Bio-Techne

Forecast & Rating14 analysts currently cover Bio-Techne, with about 7.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $70.73, about 2.2% downside from the current price of $72.34. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 30.3% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Bio-Techne's outlook. Data as of Aug 31, 2026; for reference only and not investment advice.